- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04720976
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
May 16, 2023 updated by: Jacobio Pharmaceuticals Co., Ltd.
A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients With Advanced Solid Tumors
To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
To assess the safety and tolerability and determine the Recommended phase 2 dose (RP2D) of JAB-3312 in combination with PD1 inhibitor or MEK inhibitor in patients with advanced solid tumors.
Study Type
Interventional
Enrollment (Anticipated)
200
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jacobio Pharmaceuticals
- Phone Number: 86 10 56315466
- Email: clinicaltrials@jacobiopharma.com
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Recruiting
- Research Site
-
Scottsdale, Arizona, United States, 85259
- Not yet recruiting
- Research Site
-
-
California
-
Los Angeles, California, United States, 90033
- Recruiting
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Research Site
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Recruiting
- Research Site
-
Orange City, Florida, United States, 32763
- Recruiting
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Research Site
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, United States, 55902
- Recruiting
- Research Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63130
- Recruiting
- Research Site
-
-
New York
-
New York, New York, United States, 10016
- Recruiting
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Recruiting
- Research Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Not yet recruiting
- Research Site
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor. Some cohorts must meet specific expression or gene mutation where indicated
- Sufficient organ function
- Participants must have at least 1 measurable lesion as defined by RECIST v1.1
- Must be able to provide an archived tumor sample
- ECOG performance status score of 0 or 1.
Exclusion Criteria:
- History of cancer that is histologically distinct from the cancers under study
- Active or untreated central nervous system (CNS) metastases
- History of pneumonitis or interstitial lung disease (ILD)
- Has active hepatitis B, hepatitis C infection, HIV
- Any severe and/or uncontrolled medical conditions
- LVEF ≤50%
- QTcF >470 msec
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: JAB-3312+Pembrolizumab dose escalation
Dose escalation
|
JAB-3312 will be administered orally, variable dose.
Pembrolizumab will be administered as an intravenous infusion.
|
Experimental: JAB-3312+ Binimetinib dose escalation
Dose escalation
|
JAB-3312 will be administered orally, variable dose.
Binimetinib will be administered orally.
|
Experimental: JAB-3312+Pembrolizumab dose expansion
Dose expansion
|
JAB-3312 will be administered orally, variable dose.
Pembrolizumab will be administered as an intravenous infusion.
|
Experimental: JAB-3312+Binimetinib dose expansion
Dose expansion
|
JAB-3312 will be administered orally, variable dose.
Binimetinib will be administered orally.
|
Experimental: JAB-3312+Sotorasib dose escalation
Dose escalation
|
JAB-3312 will be administered orally, variable dose.
Sotorasib will be administered orally.
|
Experimental: JAB-3312+ Osimertinib dose escalation
Dose escalation
|
JAB-3312 will be administered orally, variable dose.
Osimertinib will be administered orally.
|
Experimental: JAB-3312+ Sotorasib dose expansion
Dose expansion
|
JAB-3312 will be administered orally, variable dose.
Sotorasib will be administered orally.
|
Experimental: JAB-3312+ Osimertinib dose expansion
Dose expansion
|
JAB-3312 will be administered orally, variable dose.
Osimertinib will be administered orally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with dose limiting toxicities
Time Frame: 24 months
|
Incidence of dose limiting toxicities (DLTs) in the dose escalation phase.
A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle.
(Dose escalation phase)
|
24 months
|
Objective response rate (ORR)
Time Frame: 24 months
|
ORR is defined as the proportion of participants with complete response or partial response (CR+PR).
(Dose expansion phase)
|
24 months
|
Duration of response (DOR)
Time Frame: 24 months
|
DOR is defined as the time from the participant's initial objective response (CR or PR) to study drug therapy, to disease progression or death due to any cause, whichever occurs first.
(Dose expansion phase)
|
24 months
|
Duration of response (DCR)
Time Frame: 24 months
|
DCR is defined as proportion of participants with complete response, partial response, stable disease(CR+PR+SD).
(Dose expansion phase)
|
24 months
|
Progression-free survival (PFS)
Time Frame: 24 months
|
PFS is defined as the interval of time between the date of first treatment to the earliest date of disease progression or death which occurs first.
(Dose expansion phase)
|
24 months
|
Overall survival (OS)
Time Frame: 24 months
|
OS is defined as the interval of time between the date of first treatment until death, loss to follow up or termination of the study by the sponsor.
(Dose expansion phase)
|
24 months
|
Number of participants with adverse events
Time Frame: 24 months
|
All patients participating in this study will be assessed for incidence and severity of adverse events (AEs) and serious AEs, including changes in laboratory values, vital signs, electrocardiograms, cardiac imaging and ophthalmological assessments (Dose escalation phase)
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: 24 months
|
PFS is defined as the interval of time between the date of first treatment to the earliest date of disease progression or death which occurs first.
(Dose escalation phase)
|
24 months
|
Overall survival (OS)
Time Frame: 24 months
|
OS is defined as the interval of time between the date of first treatment until death, loss to follow up or termination of the study by the sponsor(Dose escalation phase)
|
24 months
|
Objective response rate (ORR)
Time Frame: 24 months
|
ORR is defined as the proportion of participants with complete response or partial response (CR+PR).
(Dose escalation phase)
|
24 months
|
Duration of response (DOR)
Time Frame: 24 months
|
DOR is defined as the time from the participant's initial objective response (CR or PR) to study drug therapy, to disease progression or death due to any cause, whichever occurs first.
(Dose escalation phase)
|
24 months
|
Duration of response (DCR)
Time Frame: 24 months
|
DCR is defined as proportion of participants with complete response, partial response, stable disease(CR+PR+SD).
(Dose escalation phase)
|
24 months
|
Plasma concentration (Cmax)
Time Frame: 24 months
|
Highest observed plasma concentration of JAB-3312(dose escalation phase)
|
24 months
|
Time to achieve Cmax (Tmax)
Time Frame: 24 months
|
Time of highest observed plasma concentration of JAB-3312(dose escalation phase)
|
24 months
|
Area under the plasma concentration-time curve (AUC)
Time Frame: 24 months
|
Area under the plasma concentration time curve of JAB-3312(dose escalation phase)
|
24 months
|
Number of participants with adverse events
Time Frame: 24 months
|
All patients participating in this study will be assessed for incidence and severity of adverse events (AEs) and serious AEs, including changes in laboratory values, vital signs, electrocardiograms, cardiac imaging and ophthalmological assessments (Dose expansion phase)
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 23, 2021
Primary Completion (Anticipated)
January 5, 2024
Study Completion (Anticipated)
February 5, 2024
Study Registration Dates
First Submitted
January 18, 2021
First Submitted That Met QC Criteria
January 21, 2021
First Posted (Actual)
January 22, 2021
Study Record Updates
Last Update Posted (Actual)
May 18, 2023
Last Update Submitted That Met QC Criteria
May 16, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- JAB-3312-1003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC
-
Shanghai Henlius BiotechCompleted
-
The Netherlands Cancer InstituteEnrolling by invitation
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Bio-Thera SolutionsCompleted
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
TYK Medicines, IncRecruiting
-
Radboud University Medical CenterPfizer; ImaginAb, Inc.; University Hospital TuebingenNot yet recruitingNSCLCGermany, Netherlands
-
Beta Pharma, Inc.Completed
Clinical Trials on JAB-3312
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingColorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Carcinoma | KRAS P.G12CChina
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingBreast Cancer | Colorectal Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Other Solid Tumors | Pancreatic Ductal CarcinomaUnited States
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingBreast Cancer | Colorectal Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Other Solid Tumors | Pancreatic Ductal CarcinomaChina
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingNSCLC | AML | SCLC | Ovarian Carcinoma | Malignant Tumor | ESCC | CRPC | MFChina
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingSolid Tumors, AdultUnited States
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingNon-small Cell Lung CancerChina
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingNSCLC | Solid Tumor | CRCChina
-
Jacobio Pharmaceuticals Co., Ltd.Not yet recruiting
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingHead and Neck Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Other Metastatic Solid TumorsChina
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingHead and Neck Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Other Metastatic Solid TumorsUnited States